Evolution of the Average Target: TG Therapeutics, Inc.

Evolution of the Target Price: TG Therapeutics, Inc.

Changes in Analyst Recommendations: TG Therapeutics, Inc.

20d8ccbf.J31M3HVD8JjQHak46BI2HGp3gGlJ6v1E3zH4uCaXz0I.RRoY8QYaseuFZJtuoV4AXjkF9zABv5E1umSU1030pBJTPAC6IA2y7IF1mQ~956e4c623691c032f1a9d488cb3bfe31
07-27 B. Riley Raises Price Target on TG Therapeutics to $86 From $55, Keeps Buy Rating MT
07-07 Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says MT
07-07 BofA Securities Adjusts Price Target on TG Therapeutics to $20 From $17, Maintains Underperform Rating MT
25-09-17 B. Riley Raises Price Target on TG Therapeutics to $55 From $53, Keeps Buy Rating MT
25-08-04 TG Therapeutics Q2 revenue soars, helped by BRIUMVI sales RE
25-03-04 B. Riley Raises Price Target on TG Therapeutics to $53 From $38, Keeps Buy Rating MT
25-01-07 BofA Securities Adjusts Price Target on TG Therapeutics to $10 From $9, Maintains Underperform Rating MT
24-10-29 TD Cowen Initiates TG Therapeutics at Buy With $50 Price Target MT
24-08-07 B. Riley Adjusts Target on TG Therapeutics to $34 From $29, Maintains Buy Rating MT
24-02-29 Goldman Sachs Raises Price Target on TG Therapeutics to $13 From $12, Maintains Neutral Rating MT
24-02-05 B. Riley Adjusts Price Target on TG Therapeutics to $29 From $24, Maintains Buy Rating MT
24-01-11 HC Wainwright Adjusts TG Therapeutics Price Target to $45 From $41, Maintains Buy Rating MT
23-10-20 B. Riley Adjusts Price Target on TG Therapeutics to $24 From $32, Keeps Buy Rating MT
23-08-07 JPMorgan Cuts TG Therapeutics Price Target to $22 From $34, Maintains Overweight Rating MT
23-08-02 Goldman Sachs Upgrades TG Therapeutics to Neutral From Sell, Adjusts Price Target to $12 From $16 MT
23-08-02 B. Riley Lowers TG Therapeutics' PT to $32 From $42 After Lower-Than-Expected Q2 Results, Keeps Buy Rating MT
23-08-01 HC Wainwright Adjusts TG Therapeutics' Price Target to $41 From $34, Keeps Buy Rating MT
23-07-24 Goldman Sachs Adjusts TG Therapeutics' Price Target to $16 From $10, Keeps Sell Rating MT
23-05-02 Ladenburg Thalmann Raises Price Target on TG Therapeutics to $37.50 From $26, Maintains Buy Rating MT
23-05-02 B. Riley Raises TG Therapeutics' Price Target to $42 From $39 After 'Strong' Q1 Results, Keeps Buy Rating MT
23-04-14 HC Wainwright Adjusts Price Target on TG Therapeutics to $28 From $24, Reiterates Buy Rating MT
23-04-11 B. Riley Raises TG Therapeutics' Price Target to $39 From $23, Keeps Buy Rating MT
23-02-07 Cantor Fitzgerald Raises Price Target on TG Therapeutics to $24 From $18, Maintains Overweight Rating MT
23-01-24 Evercore ISI Adjusts Price Target on TG Therapeutics to $25 From $16, Maintains Outperform Rating MT
22-12-30 Evercore ISI Adjusts Price Target on TG Therapeutics to $16 From $11, Maintains Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+30.02%
+15.57%
+7.97%
+7.28%
+8.31%
+7.55%
+6.77%
+32.41%
-4.01%
+7.56%
Average +11.94%
Weighted average by Cap. +10.82%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
53.62USD
Average target price
69.71USD
Spread / Average Target
+30.02%
High Price Target
86.00USD
Spread / Highest target
+60.39%
Low Price Target
21.00USD
Spread / Lowest Target
-60.84%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
CCC
  1. Stock Market
  2. Stocks
  3. TGTX Stock
  4. Consensus TG Therapeutics, Inc.